g12c | Sotorasib is First KRAS Inhibitor Approved by FDA

Keyword	CPC	PCC	Volume	Score	Length of keyword
g12c	0.46	0.8	3020	60	4

Keyword	CPC	PCC	Volume	Score
g12c	1.22	0.6	4951	9
g12c mutation	0.24	0.5	2574	38
g12c inhibitor	1.64	0.3	4588	44
g12c kras	1.18	1	1491	50
g12c0000	0.53	0.1	3150	7
g12ca	1.56	0.8	1837	5
g12ci	1.02	0.3	9640	1
g12c g12d g12v	1.2	0.5	3514	78
g12c kras mutation	0.53	0.3	566	68
g12c inhibitors pancreatic cancer rna seq	1.03	0.4	764	45
g12c kras inhibitor	1.99	1	616	84

Search Results related to g12c on Search Engine

Sotorasib is First KRAS Inhibitor Approved by FDA - NCI
cancer.gov

https://www.cancer.gov/news-events/cancer-currents-blog/2021/fda-sotorasib-lung-cancer-kras

WEBJun 25, 2021 · The CodeBreaK 100 trial, funded by Amgen and NCI, is testing sotorasib (previously called AMG510) as a treatment for people with solid tumors that have KRAS G12C. The mutation, a hallmark of damage from cigarette smoke, is …

DA: 71 PA: 53 MOZ Rank: 55

KRAS mutation: from undruggable to druggable in cancer
nature.com

https://www.nature.com/articles/s41392-021-00780-4

WEBNov 15, 2021 · Excitingly, AMG510 was the first drug-targeting KRAS (G12C) to be approved for clinical use this year. This review summarises the most recent understanding of fundamental aspects of KRAS, the...

DA: 5 PA: 98 MOZ Rank: 97

FDA Approves First Targeted Therapy for Lung Cancer Mutation …
fda.gov

https://www.fda.gov/news-events/press-announcements/fda-approves-first-targeted-therapy-lung-cancer-mutation-previously-considered-resistant-drug

WEBFor Immediate Release: May 28, 2021. Today, the U.S. Food and Drug Administration approved Lumakras (sotorasib) as the first treatment for adult patients with non-small cell lung cancer whose...

DA: 30 PA: 62 MOZ Rank: 32

The KRAS-G12C inhibitor: activity and resistance - Nature
nature.com

https://www.nature.com/articles/s41417-021-00383-9

WEBSep 1, 2021 · The KRAS-G12C inhibitor: activity and resistance | Cancer Gene Therapy. Editorial. Published: 01 September 2021. The KRAS-G12C inhibitor: activity and resistance. Jiao Liu, Rui Kang &...

DA: 25 PA: 40 MOZ Rank: 45

KRAS G12C Inhibition with Sotorasib in Advanced Solid Tumors
nejm.org

https://www.nejm.org/doi/full/10.1056/NEJMoa1917239

WEBSep 20, 2020 · The KRAS p.G12C mutation occurs in 13% of non–small-cell lung cancers (NSCLCs) and in 1 to 3% of colorectal cancers and other cancers. Sotorasib is a small molecule that selectively and...

DA: 55 PA: 5 MOZ Rank: 98

Acquired Resistance to KRAS G12C Inhibition in Cancer
nejm.org

https://www.nejm.org/doi/full/10.1056/NEJMoa2105281

WEBN Engl J Med 2021;384: 2382 - 2393. DOI: 10.1056/NEJMoa2105281. VOL. 384 NO. 25. Abstract. Background. Clinical trials of the KRAS inhibitors adagrasib and sotorasib have shown promising activity...

DA: 30 PA: 32 MOZ Rank: 86

The path to the clinic: a comprehensive review on direct KRAS G12C
nih.gov

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8767686/

WEBJan 19, 2022 · In May 2021, the United States Food and Drug Administration (FDA) approved sotorasib (Lumakras™) as the first treatment for adult patients with non-small cell lung cancer (NSCLC) harboring the G12C genetic mutation who have received at least one prior systemic therapy.

DA: 42 PA: 83 MOZ Rank: 49

Targeting KRAS(G12C): From Inhibitory Mechanism to Modulation of
cell.com

https://www.cell.com/cell/fulltext/S0092-8674(20)31241-1

WEBTargeting KRAS (G12C): From Inhibitory Mechanism to Modulation of Antitumor Effects in Patients. Summary. KRAS mutations are among the most common genetic alterations in lung, colorectal, and pancreatic cancers.

DA: 94 PA: 14 MOZ Rank: 31

Targeting KRAS G12C in Non-Small-Cell Lung Cancer: Current …
nih.gov

https://pubmed.ncbi.nlm.nih.gov/38625662/

WEBThe discovery of a small pocket in the binding switch II region of KRAS G12C has revolutionized the treatment of KRAS G12C -mutated NSCLC patients. Sotorasib and adagrasib, direct KRAS G12C inhibitors, have been approved by the US Food and Drug Administration (FDA) and other regulatory agencies for patients with previously treated …

DA: 96 PA: 17 MOZ Rank: 83

Distribution of KRAS G12C Somatic Mutations across Race, Sex, …
nejm.org

https://www.nejm.org/doi/full/10.1056/NEJMc2030638

WEBJan 13, 2021 · Overall, we found that KRASG12C somatic mutations are common in NSCLC, colorectal cancer, appendiceal and small bowel cancers, and cancers of unknown primary site, with a mutation frequency of 3...

DA: 97 PA: 68 MOZ Rank: 33